WSJ - US Business

Celgene to Buy Impact Biomedicines

Celgene Corp. agreed to buy blood-disease biotechnology company Impact Biomedicines for as much as $ 7 billion.

Celgene will make an upfront payment of $ 1.1 billion for the privately held San Diego company, the companies said in a statement Sunday, confirming an earlier report in The Wall Street Journal.

Assuming Impact hits regulatory-approval…

WSJ.com: US Business

Click to comment
Loading Facebook Comments ...

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top